BPH Surgical Treatment Market

The report "BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030", is expected to grow from USD 12.62 billion in 2024 to 17.19 billion in 2030 at a CAGR of 5.3% over the span of the forecast period,

Browse 368 market data Tables and 59 Figures spread through 328 Pages and in-depth TOC on "BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/benign-prostatic-hyperplasia-treatment-market-198000374.html

The rising prevalence of benign prostatic hyperplasia, and rising cases of obesity in males. Also, the preference for minimally invasive surgeries is an expected growth opportunity for players operating in this market. However, the side-effects associated with benign prostatic hyperplasia medications and the high cost of BPH surgical treatment market are expected to restrain the market growth to a certain extent.

In 2023, the alpha-blockers segment held the largest share of the BPH Surgical Treatment, by drug type segment.

Based on drug type, the global BPH Surgical Treatment market is segmented into alpha-blockers, 5-alpha reductase inhibitors, and other drug types. In 2023, alpha-blockers led the BPH Surgical Treatment market the large market share of this segment is driven by the large share and the high growth rate of this segment can be attributed to the ability of these drugs to relax muscles and improve urine flow, thus reducing bladder outlet obstruction.

“The TURP segment is projected to witness the highest growth rate in the BPH Surgical Treatment market, in 2023, by type”

The market for BPH Surgical Treatment type is divided into segments based on Transurethral Resection of the Prostate (TURP), Laser Surgery, UroLift Procedure, Rezum Procedure, Robot-assisted waterjet ablation, Prostatic Stenting, Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic arterial embolization (PAE) and Others. Transurethral Resection of the Prostate (TURP) is a significant contributor to the growth of the BPH Surgical Treatment type segment. Additionally, TURP is known as the gold standard treatment as it is a well-established and cost-effective first-line preferred treatment procedure of Benign Prostatic Hyperplasia, this segment of the BPH Surgical Treatment market is projected to develop at the fastest rate.

The North American market has the highest share of the BPH Surgical Treatment market in 2023.

The global BPH Surgical Treatment market is segmented into six distinct regions: North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and GCC Countries. North America holds the highest share in the global BPH Surgical Treatment market in 2023. The large share of North America can be attributed to the region's highly developed healthcare infrastructure and reimbursement system, the increasing number of advanced treatment procedures like UroLift Procedure, Rezum Procedure, Robot-assisted waterjet ablation and Prostatic Stenting, and patient awareness about the newly introduced treatment procedures and technologies in the market drive the North American market growth.

Prominent players in the BPH Surgical Treatment market drug type include GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc.(Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India). And BPH Surgical Treatment type includes Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark), IPG Photonics Corporation (Russia), ProstaLund AB (Sweden), Karl Storz Se & Co. KG (Germany), Richard Wolf Gmbh (Germany), and Quanta System (Italy).

Don’t miss out on business opportunities in BPH Surgical Treatment Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com